Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC
Details : EG12014, biosimilar of trastuzumab, is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Receives Positive CHMP Opinion for Breast and Gastric Cancer Biosimilar Trastuzumab
Details : EG12014, biosimilar of trastuzumab, is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EG1206A (pertuzumab) targets the extracellular dimerization domain (Subdomain II) of the HER2 and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Sacura GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Sacura GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Submits Biologics License Application for Proposed Biosimilar Trastuzumab to US FDA
Details : Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers. Sandoz is seeking approval for the same indications as the reference medicine.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 22, 2021
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar
Details : The purpose of the trial was to demonstrate the therapeutic equivalence in terms of efficacy between EG12014 to Herceptin®, and to compare the safety, immunogenicity and PK between the two trastuzumab products.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 14, 2018
Lead Product(s) : EG12014
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 08, 2017
Lead Product(s) : EG12014
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable